Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dosimetry and Immunohistochemistry Study to Establish Radiolabelled PSMA as a Potential Target in Glioma Treatment

NCT05263466 is registered in ClinicalTrials.gov with King's College Hospital NHS Trust as lead sponsor.

NCT NCT05263466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05263466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dosimetry and Immunohistochemistry Study to Establish Radiolabelled PSMA as a Potential Target in Glioma Treatment
Lead sponsor
King's College Hospital NHS Trust
Phase
Not applicable
Overall status
Not yet recruiting
Start date
August 1, 2022
Completion date
May 1, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, malignant